Somatic Gene-Mutated Cancer Panels

TARGT

Tumor Associated drug Response by Genomic Testing

4baseCare’s TARGT portfolio offers a series of tumor tests that allows a better understanding of an individual’s disease through deep molecular profiling of the tumors generated through detailed bioinformatics and clinical analysis.

The results provide an edge to oncologist(s) to choose the best personalized therapy options covering genomics impact factors, based on specific mutations and molecular signatures associated with a patient’s tumor testing sample.